Article Information
History
- November 17, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Yushi Nomura1,2,
- Michiru Sawahata1,3,*,
- Yosikazu Nakamura4,
- Ryousuke Koike1,2,
- Otohiro Katsube1,
- Koichi Hagiwara3,
- Seiji Niho2,
- Norihiro Masuda5,
- Takaaki Tanaka6 and
- Kumiya Sugiyama1,7
- 1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
- 2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University
- 3Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University
- 4Department of Public Health, Jichi Medical University
- 5Department of Surgery, National Hospital Organization Utsunomiya National Hospital
- 6Department of Orthopaedic Surgery, National Hospital Organization Utsunomiya National Hospital
- 7Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center
- ↵*Corresponding author full contact details:
Michiru Sawahata, Division of Pulmonary Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan., Tel.: +81-285587350, Fax: +81-285443586, Email: sawahata{at}jichi.ac.jp
Posted November 17, 2021.
Attenuation of antibody titres during 3-6 months after the second dose of the BNT162b2 vaccine depends on sex, with age and smoking as risk factors for lower antibody titres at 6 months
